EPHA5
Summary: This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Aug 2013].
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
EPH receptor A5 | MIM:600004 | Ensembl:ENSG00000145242 | HGNC:HGNC:3389 | PA27821 | 4q13.1-q13.2 |
GO terms in EPHA5
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
BP | IBA | GO:0007275 | multicellular organism development |
BP | ISS | GO:0007411 | axon guidance |
BP | IBA | GO:0009968 | negative regulation of signal transduction |
BP | IEA | GO:0018108 | peptidyl-tyrosine phosphorylation |
BP | ISS | GO:0019933 | cAMP-mediated signaling |
BP | ISS | GO:0021766 | hippocampus development |
BP | IBA | GO:0030154 | cell differentiation |
BP | ISS | GO:0032793 | positive regulation of CREB transcription factor activity |
BP | ISS | GO:0032956 | regulation of actin cytoskeleton organization |
BP | IBA | GO:0033674 | positive regulation of kinase activity |
BP | IBA | GO:0043066 | negative regulation of apoptotic process |
BP | ISS | GO:0043087 | regulation of GTPase activity |
BP | IBA | GO:0043410 | positive regulation of MAPK cascade |
BP | ISS | GO:0048013 | ephrin receptor signaling pathway |
BP | TAS | GO:0048013 | ephrin receptor signaling pathway |
BP | IEP | GO:0048666 | neuron development |
BP | ISS | GO:0061178 | regulation of insulin secretion involved in cellular response to glucose stimulus |
BP | IBA | GO:0070374 | positive regulation of ERK1 and ERK2 cascade |
CC | IBA | GO:0005737 | cytoplasm |
CC | IDA | GO:0005791 | rough endoplasmic reticulum |
CC | IDA | GO:0005886 | plasma membrane |
CC | TAS | GO:0005886 | plasma membrane |
CC | IBA | GO:0005887 | integral component of plasma membrane |
CC | IEA | GO:0005887 | integral component of plasma membrane |
CC | IDA | GO:0009897 | external side of plasma membrane |
CC | IEA | GO:0030424 | axon |
CC | IDA | GO:0030425 | dendrite |
CC | IBA | GO:0043005 | neuron projection |
CC | IDA | GO:0043025 | neuronal cell body |
CC | IBA | GO:0043235 | receptor complex |
CC | IDA | GO:0048471 | perinuclear region of cytoplasm |
MF | IBA | GO:0004709 | MAP kinase kinase kinase activity |
MF | IBA | GO:0004713 | protein tyrosine kinase activity |
MF | IBA | GO:0004714 | transmembrane receptor protein tyrosine kinase activity |
MF | IBA | GO:0004888 | transmembrane signaling receptor activity |
MF | ISS | GO:0005003 | ephrin receptor activity |
MF | ISS | GO:0005004 | GPI-linked ephrin receptor activity |
MF | IBA | GO:0005005 | transmembrane-ephrin receptor activity |
MF | NAS | GO:0005005 | transmembrane-ephrin receptor activity |
MF | IEA | GO:0005524 | ATP binding |
MF | IBA | GO:0031434 | mitogen-activated protein kinase kinase binding |
Gene expression in normal tissue: EPHA5
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in EPHA5
Database | Pathway ID | Pathway Des. |
---|---|---|
kegg | hsa04360 | Axon guidance - Homo sapiens (human) |
pid | epha_fwdpathway | EPHA forward signaling |
pid | ephrinarevpathway | Ephrin A reverse signaling |
reactome | R-HSA-1266738 | Developmental Biology |
reactome | R-HSA-1266738 | Developmental Biology |
reactome | R-HSA-2682334 | EPH-Ephrin signaling |
reactome | R-HSA-2682334 | EPH-Ephrin signaling |
reactome | R-HSA-3928663 | EPHA-mediated growth cone collapse |
reactome | R-HSA-3928663 | EPHA-mediated growth cone collapse |
reactome | R-HSA-3928665 | EPH-ephrin mediated repulsion of cells |
reactome | R-HSA-3928665 | EPH-ephrin mediated repulsion of cells |
reactome | R-HSA-422475 | Axon guidance |
reactome | R-HSA-422475 | Axon guidance |
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD885 | Compound 110 | 1 |
iGMDRD318 | PAC-1 | 5 |
iGMDRD52 | Rotenone | 2 |
iGMDRD187 | BRD9876 | 3 |
iGMDRD491 | TAE-684 | 1 |
iGMDRD23 | Gossypol | 4 |
iGMDRD64 | Parbendazole | 6 |
iGMDRD398 | Sepantronium | 2 |
iGMDRD399 | Selumetinib | 3 |
iGMDRD74 | Idarubicin | 3 |
iGMDRD887 | Compound 23 citrate | 3 |
iGMDRD781 | Sirolimus | 1 |
iGMDRD144 | NSC95397 | 2 |
iGMDRD670 | ML 210 | 3 |
iGMDRD76 | Simvastatin | 2 |
iGMDRD151 | CHM-1 | 7 |
iGMDRD433 | Lexibulin | 1 |
iGMDRD554 | CHEMBL1434137 | 3 |
iGMDRD210 | AC55649 | 3 |
iGMDRD634 | SCHEMBL2608041 | 1 |
iGMDRD394 | BX-795 | 4 |
iGMDRD466 | Chaetocin | 2 |
iGMDRD280 | CYTOCHALASIN B | 6 |
iGMDRD316 | N9-Isopropyl-olomoucine | 3 |
iGMDRD193 | Fqi1 | 3 |
iGMDRD152 | 179324-69-7 | 5 |
iGMDRD446 | LY 2183240 | 1 |
iGMDRD481 | Dactolisib | 2 |
iGMDRD221 | Tamoxifen | 1 |
iGMDRD705 | Nakiterpiosin | 3 |
iGMDRD105 | Triptolide | 3 |
iGMDRD103 | SN-38 | 2 |
iGMDRD202 | Curcumin | 3 |
iGMDRD158 | NSC141540 | 2 |
iGMDRD121 | GMX1778 | 6 |
iGMDRD322 | FK 866 | 6 |
iGMDRD886 | Compound 1541A | 2 |
iGMDRD505 | Pevonedistat | 2 |
iGMDRD329 | Merck60 | 2 |
iGMDRD871 | BRD6368 | 2 |
iGMDRD286 | Nsc 632839 | 2 |
iGMDRD414 | MST-312 | 5 |
iGMDRD701 | NVP-AUY922 | 5 |
iGMDRD405 | PIK-75 | 2 |
iGMDRD150 | RITA | 3 |
iGMDRD424 | Tamatinib | 2 |
iGMDRD345 | Compound 10b [PMID: 11504634] | 2 |
iGMDRD512 | nutlin 3 | 5 |
iGMDRD607 | Ubistatin B | 2 |
iGMDRD84 | Lovastatin acid | 4 |
iGMDRD48 | Dexamethasone | 2 |
iGMDRD945 | ML214 | 2 |
iGMDRD883 | CIL55A | 2 |
iGMDRD901 | ELCPK | 8 |
iGMDRD211 | (1S,3R)-RSL3 | 3 |
iGMDRD123 | Isoevodiamine | 5 |
iGMDRD698 | Neratinib | 5 |
iGMDRD57 | Chloropentafluorobenzene | 2 |
iGMDRD351 | GW843682X | 2 |
iGMDRD499 | PDMP | 3 |
iGMDRD237 | ABT-751 | 2 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in EPHA5